Ionis rolls out promising PhIII data on volanesorsen for rare enzyme disorder, but safety questions linger
Ionis has nailed down positive Phase III data on its lead experimental drug volanesorsen, used to combat rare cases of familial chylomicronemia syndrome. But the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
